Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?

Eur Heart J. 2012 Sep;33(18):2258-64. doi: 10.1093/eurheartj/ehs168. Epub 2012 Jul 5.

Authors

Aroon D Hingorani¹, Reecha Sofat, Richard W Morris, Peter Whincup, Gordon D Lowe, Jennifer Mindell, Naveed Sattar, Juan P Casas, Tina Shah

Affiliation

¹ Genetic Epidemiology Group, Research Department of Epidemiology and Public Health, Division of Population Health, University College London, Torrington Place, London WC1E 6BT, UK.

PMID: 22766581
DOI: 10.1093/eurheartj/ehs168

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers / metabolism
C-Reactive Protein / drug effects
C-Reactive Protein / metabolism*
Cardiovascular Diseases / diagnosis*
Cardiovascular Diseases / prevention & control
Clinical Trials as Topic
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Regression Analysis
Risk Assessment
Risk Factors

Substances

Biomarkers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
C-Reactive Protein

Grants and funding